Endocrinology

Endocrinology includes companies working on hormone-related disease, including diabetes, adrenal disorders, thyroid disease, and other metabolic or gland-driven conditions. It is a useful grouping for following companies exposed to chronic hormone-regulated disease categories.

Why watch Endocrinology

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Endocrinology news

The latest feed items from companies currently grouped under Endocrinology.

1. 01
   2026-08-07 12:30 EST

   NBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

   Source: Neurocrine Biosciences

2. 02
   2026-08-03 20:05 EST

   CRNXCrinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

   Source: Crinetics Pharmaceuticals

3. 03
   2026-07-30 20:01 EST

   NBIXNeurocrine Biosciences Reports Second-Quarter 2026 Financial Results

   Source: Neurocrine Biosciences

4. 04
   2026-07-29 20:05 EST

   CORTCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

   Source: Corcept

5. 05
   2026-07-29 20:05 EST

   VKTXViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

   Source: Viking Therapeutics

6. 06
   2026-07-23 20:05 EST

   NBIXNeurocrine Biosciences Announces Key Leadership Hiring, Promotions

   Source: Neurocrine Biosciences

7. 07
   2026-07-23 11:05 EST

   VKTXViking Therapeutics Appoints Dorothy Gemmell to Board of Directors

   Source: Viking Therapeutics

8. 08
   2026-07-22 20:05 EST

   CORTCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

   Source: Corcept

9. 09
   2026-07-22 20:05 EST

   VKTXViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

   Source: Viking Therapeutics

10. 10
    2026-07-21 20:05 EST

    NBIXNeurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

    Source: Neurocrine Biosciences

11. 11
    2026-07-09 20:01 EST

    NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

    Source: Neurocrine Biosciences

12. 12
    2026-07-01 20:05 EST

    NBIXNeurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

    Source: Neurocrine Biosciences

13. 13
    2026-06-30 20:05 EST

    CRNXCrinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

    Source: Crinetics Pharmaceuticals

14. 14
    2026-06-24 11:05 EST

    VKTXViking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

    Source: Viking Therapeutics

15. 15
    2026-06-17 20:28 EST

    CORTCorcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

    Source: Corcept

16. 16
    2026-06-15 20:10 EST

    NBIXSoleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period

    Source: Neurocrine Biosciences

17. 17
    2026-06-15 20:05 EST

    NBIXNeurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

    Source: Neurocrine Biosciences

18. 18
    2026-06-15 12:35 EST

    NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026

    Source: Neurocrine Biosciences

19. 19
    2026-06-15 12:30 EST

    NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026

    Source: Neurocrine Biosciences

20. 20
    2026-06-14 20:30 EST

    CRNXCrinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

    Source: Crinetics Pharmaceuticals

Companies in Endocrinology

6 companies tagged with Endocrinology.

Frequently Asked Questions